Bioceramic Bone Graft Substitute for Treatment of Unicameral Bone Cysts
Purpose To review the outcome of 12 patients who underwent debridement and injection of bioceramic for unicameral bone cyst (UBC). The resorption rate of the bioceramic was estimated by both traditional and novel methods. Methods Records of 10 males and 2 females aged 6 to 34 years who underwent deb...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-08-01
|
| Series: | Journal of Orthopaedic Surgery |
| Online Access: | https://doi.org/10.1177/1602400220 |
| _version_ | 1818142917929205760 |
|---|---|
| author | Yale A Fillingham Gregory L Cvetanovich Bryan D Haughom Brandon J Erickson Steven Gitelis |
| author_facet | Yale A Fillingham Gregory L Cvetanovich Bryan D Haughom Brandon J Erickson Steven Gitelis |
| author_sort | Yale A Fillingham |
| collection | DOAJ |
| description | Purpose To review the outcome of 12 patients who underwent debridement and injection of bioceramic for unicameral bone cyst (UBC). The resorption rate of the bioceramic was estimated by both traditional and novel methods. Methods Records of 10 males and 2 females aged 6 to 34 years who underwent debridement and injection of bioceramic for UBC and were followed up for a mean of 41 (range, 26–57) months were reviewed. Functional outcome was assessed using the self-completed Musculoskeletal Tumor Society (MSTS) questionnaire. Radiological outcome was assessed using both original and modified Neer Outcome Rating System. The resorption rate of the bioceramic was estimated using both traditional and novel (ImageJ) methods. Results The mean MSTS score was 29.7 (range, 28–30) indicating excellent functional outcome. Of the 12 patients, 9 achieved complete healing and 3 had a residual cyst of 1%, 11%, and 52%. The last was considered a local recurrence, and the patient underwent repeat percutaneous injection of the bioceramic 1.5 years later and remained disease-free 4 years later. The mean resorption rate was 29% faster when estimated using the traditional rather than the ImageJ method (0.47 vs. 0.33 cm 3 /day, p=0.02). In the patient with recurrence, the resorption rate was faster than the average (0.68 vs. 0.33 cm 3 /day). Conclusion A single percutaneous injection of the bioceramic for UBC achieved good functional and radiological outcome while avoiding donor-site morbidity. |
| first_indexed | 2024-12-11T11:23:24Z |
| format | Article |
| id | doaj.art-ab9830814a4e403a91c59aaef2c07982 |
| institution | Directory Open Access Journal |
| issn | 2309-4990 |
| language | English |
| last_indexed | 2024-12-11T11:23:24Z |
| publishDate | 2016-08-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Orthopaedic Surgery |
| spelling | doaj.art-ab9830814a4e403a91c59aaef2c079822022-12-22T01:09:06ZengSAGE PublishingJournal of Orthopaedic Surgery2309-49902016-08-012410.1177/1602400220Bioceramic Bone Graft Substitute for Treatment of Unicameral Bone CystsYale A FillinghamGregory L CvetanovichBryan D HaughomBrandon J EricksonSteven GitelisPurpose To review the outcome of 12 patients who underwent debridement and injection of bioceramic for unicameral bone cyst (UBC). The resorption rate of the bioceramic was estimated by both traditional and novel methods. Methods Records of 10 males and 2 females aged 6 to 34 years who underwent debridement and injection of bioceramic for UBC and were followed up for a mean of 41 (range, 26–57) months were reviewed. Functional outcome was assessed using the self-completed Musculoskeletal Tumor Society (MSTS) questionnaire. Radiological outcome was assessed using both original and modified Neer Outcome Rating System. The resorption rate of the bioceramic was estimated using both traditional and novel (ImageJ) methods. Results The mean MSTS score was 29.7 (range, 28–30) indicating excellent functional outcome. Of the 12 patients, 9 achieved complete healing and 3 had a residual cyst of 1%, 11%, and 52%. The last was considered a local recurrence, and the patient underwent repeat percutaneous injection of the bioceramic 1.5 years later and remained disease-free 4 years later. The mean resorption rate was 29% faster when estimated using the traditional rather than the ImageJ method (0.47 vs. 0.33 cm 3 /day, p=0.02). In the patient with recurrence, the resorption rate was faster than the average (0.68 vs. 0.33 cm 3 /day). Conclusion A single percutaneous injection of the bioceramic for UBC achieved good functional and radiological outcome while avoiding donor-site morbidity.https://doi.org/10.1177/1602400220 |
| spellingShingle | Yale A Fillingham Gregory L Cvetanovich Bryan D Haughom Brandon J Erickson Steven Gitelis Bioceramic Bone Graft Substitute for Treatment of Unicameral Bone Cysts Journal of Orthopaedic Surgery |
| title | Bioceramic Bone Graft Substitute for Treatment of Unicameral Bone Cysts |
| title_full | Bioceramic Bone Graft Substitute for Treatment of Unicameral Bone Cysts |
| title_fullStr | Bioceramic Bone Graft Substitute for Treatment of Unicameral Bone Cysts |
| title_full_unstemmed | Bioceramic Bone Graft Substitute for Treatment of Unicameral Bone Cysts |
| title_short | Bioceramic Bone Graft Substitute for Treatment of Unicameral Bone Cysts |
| title_sort | bioceramic bone graft substitute for treatment of unicameral bone cysts |
| url | https://doi.org/10.1177/1602400220 |
| work_keys_str_mv | AT yaleafillingham bioceramicbonegraftsubstitutefortreatmentofunicameralbonecysts AT gregorylcvetanovich bioceramicbonegraftsubstitutefortreatmentofunicameralbonecysts AT bryandhaughom bioceramicbonegraftsubstitutefortreatmentofunicameralbonecysts AT brandonjerickson bioceramicbonegraftsubstitutefortreatmentofunicameralbonecysts AT stevengitelis bioceramicbonegraftsubstitutefortreatmentofunicameralbonecysts |